Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network: Clinical Trials Development & Member Site Core

加拿大癌症试验组 - 加拿大合作临床试验网络：临床试验开发

基本信息

批准号：
10116970
负责人：
Janet Ellen Dancey
金额：
$ 59.54万
依托单位：
QUEEN'S UNIVERSITY AT KINGSTON
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-05-06 至 2025-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10116970
关键词：
Address Adolescent Adolescent and Young Adult Adult Advocacy Awareness Brain Breast Canada Cancer Biology Cell Therapy Child Clinical Trials Clinical Trials Design Clinical Trials Network Clinical Trials Unit Collaborations Collection Communication Communication Tools Conduct Clinical Trials Consent Forms Continuing Education Data Set Development Diagnosis Education Ensure Ethics Head and Neck Cancer Health Hematology Human Resources Image Information Technology Institutional Review Boards International Intervention Joints Leadership Lung Malignant Neoplasms Malignant neoplasm of gastrointestinal tract Molecular Monitor Operative Surgical Procedures Patients Pharmacotherapy Policies Population Process Protocols documentation Recommendation Regulation Research Research Personnel Role Scientific Advances and Accomplishments Site Skin Societies Technology Testing Time Translational Research Translations Work cancer therapy clinical development data sharing digital health experience improved innovation lifestyle intervention member method development novel therapeutics precision medicine rare cancer research clinical testing technology development tool urologic web portal working group

项目摘要

Summary The transformational advances in cancer biology and technologies to characterize cancers at a molecular level, combined with the rapid expansion of novel drugs and cellular therapies, mandates a fundamental re- evaluation of clinical trial design and delivery to ensure maximal patient and societal benefits. The Canadian Cancer Trials Group (CCTG) has strong partnerships with US investigators and groups within the NCTN, which emphasize international collaboration to conduct definitive practice-changing trials, trials in rare cancers settings, and trials testing precision-medicine strategies. As the Canadian Collaborating Clinical Trials Network (CCCTN) of the NCTN, CCTG expands NCTN's scientific expertise by: 1) Involving the best and brightest within its network in NCTN leadership roles; 2) Increasing clinical trial capacity through its national network, which includes all centres in Canada; and, 3) Facilitates access to Canadian patients, which is particularly important for trials testing interventions in rare populations. CCTG contributes to scientific concept development, accrual, biospecimen collection, and network leadership, and has expertise in instrumental components of trial conduct (including information technology and regulations). CCTG develops and participates in NCTN adult cancer trial portfolios in breast, lung, urological, and gastrointestinal malignancies, in uncommon/rare settings of unmet need such as hematological, skin, brain and head and neck cancers, and includes adolescents and young adults on AYA trials. In addition, CCTG capitalizes on opportunities to extend its scope of trial activity to include surgical and lifestyle interventions and imaging and digital health endpoints. Research incorporates translational science and other correlative endpoints to enrich information derived from NCTN trials and methods and technology development to improve clinical trial designs, endpoints, and execution. Finally, CCTG contributes trial datasets from NCTN trials as part of its data sharing policy. As the CCCTN, CCTG, Canada's largest and most experienced clinical trials unit, creates and delivers innovative strategies that arise from the NCTN accelerating the translation of scientific advances into improvements in cancer treatments improving the lives of children, adolescents, and adults diagnosed with cancer.

概括癌症生物学和分子表征癌症技术的变革性进展水平，加上新药和细胞疗法的快速扩展，要求进行根本性的重新调整评估临床试验设计和实施，以确保患者和社会利益最大化。这加拿大癌症试验组 (CCTG) 与美国研究人员和内部团体建立了牢固的合作伙伴关系 NCTN，强调国际合作以进行明确的改变实践的试验、试验在罕见癌症环境中，以及测试精准医疗策略的试验。作为加拿大合作 NCTN 的临床试验网络 (CCCTN)，CCTG 通过以下方式扩展了 NCTN 的科学专业知识：1) 让网络中最优秀、最聪明的人才担任 NCTN 的领导职务； 2）增加临床试验通过其全国网络（包括加拿大的所有中心）提供能力；以及，3) 方便访问加拿大患者，这对于测试稀有人群干预措施的试验尤其重要。 CCTG 为科学概念的发展、权责发生制、生物样本收集和网络领导做出贡献，并且拥有试验实施的工具组成部分的专业知识（包括信息技术和法规）。 CCTG 开发并参与 NCTN 成人癌症试验组合，涉及乳腺癌、肺癌、泌尿系统和胃肠道恶性肿瘤，在未满足需求的罕见/罕见情况下，例如血液癌、皮肤癌、脑癌和头颈癌，包括 AYA 中的青少年和年轻人试验。此外，CCTG 利用机会扩大其试验活动范围，将外科手术包括在内生活方式干预以及影像和数字健康终点。研究包含转化科学和其他相关终点，以丰富从 NCTN 试验和方法中获得的信息，技术开发以改进临床试验设计、终点和执行。最后，CCTG 作为其数据共享政策的一部分，贡献来自 NCTN 试验的试验数据集。作为CCCTN、CCTG、加拿大最大、最有经验的临床试验单位，创建并提供创新策略， NCTN 加速将科学进步转化为癌症改善治疗可改善被诊断患有癌症的儿童、青少年和成人的生活。